Physician profile
Peter E Zaki
NPI 1205254414
$1,618.77
in general payments reported to CMS, 2019-2025
29 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $147 · 2021: $157 · 2022: $301 · 2023: $251 · 2024: $321 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $796 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $795.56 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $222.20 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $193.06 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $149.54 | 2019-2025 | |
| Amgen INC. | $120.49 | 2020-2023 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $96.74 | 2019-2023 | Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $87.31 | 2022-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.25 | 2019-2022 | |
| Abbvie INC. | $64.32 | 2023-2025 | Ubrelvy |
| Exact Sciences Corporation | $61.27 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $55.21 | 2023-2024 | Zepbound, Jardiance, Mounjaro |
| Merck Sharp & Dohme LLC | $54.24 | 2020-2021 | |
| Daiichi Sankyo INC. | $47.64 | 2020-2024 | Injectafer |
| Biohaven Pharmaceuticals, INC. | $44.93 | 2021 | |
| Novartis Pharmaceuticals Corporation | $42.83 | 2019-2022 | |
| Amarin Pharma, INC. | $38.01 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $34.87 | 2023-2024 | |
| Boston Scientific Corporation | $30.80 | 2025 | Infinion 16 |
| Hologic Sales and Service, LLC | $24.16 | 2025 | Aptima, Thinprep 2000 Processor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.24 | 2025 | Xifaxan |
| Sanofi Pasteur INC. | $22.12 | 2019 | |
| Medtronic, INC. | $20.61 | 2025 | Inceptiv |
| Insightec,INC | $18.61 | 2023 | Exablate |
| Jazz Pharmaceuticals INC. | $17.73 | 2019 | |
| Genentech USA, INC. | $15.53 | 2020 | |
| Mannkind Corporation | $14.61 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.70 | 2022 | |
| Esperion Therapeutics, INC. | $13.54 | 2024 | Nexletol |
| Aimmune Therapeutics, INC. | $13.47 | 2024 | |
| Allergan, INC. | $12.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Zaki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.